medigraphic.com

2016, Número S1

<< Anterior Siguiente >>

Rev Med Inst Mex Seguro Soc 2016; 54 (S1)


Tratamiento de la hipertensión arterial en la enfermedad renal crónica

Palomo-Piñón S, Rosas-Peralta M, Paniagua-Sierra JR

Idioma: Español
Referencias bibliográficas: 52
Paginas: 78-88
Archivo PDF: 306.25 Kb.


RESUMEN

La hipertensión arterial (HTA) es un síndrome cardiovascular progresivo que es ocasionado por etiologías complejas e interrelacionadas. Los marcadores tempranos del síndrome frecuentemente están presentes antes de que se eleve la presión arterial (PA); por lo tanto, la HTA no puede ser solamente clasificada por el umbral de elevación de la PA. Su progresión está fuertemente asociada con anormalidades estructurales y funcionales de la función cardiaca y vascular que dañan el corazón, el riñón, el cerebro, los vasos sanguíneos y otros órganos, y provocan morbilidad y muerte prematuras. Así, la PA es solamente un biomarcador de este síndrome cardiovascular, por lo que es de mayor utilidad considerar los patrones individuales de PA del enfermo en vez de un umbral de PA único. El estudio y tratamiento de la HTA en la enfermedad renal crónica (ERC) ha tenido avances, sobre todo en la población en diálisis. El uso de tecnología no invasiva para registrar la PA ha permitido reformar la atención médica de los enfermos en cuanto al diagnóstico, patrón circadiano, vigilancia clínica, prescripción farmacológica, pronóstico y riesgo de eventos cardiovasculares. La oportunidad en el diagnóstico y tratamiento supone un retardo en la aparición de complicaciones y en el inicio de la diálisis. El bloqueo del sistema renina-angiotensina-aldosterona (SRAA), la vigilancia periódica del peso seco en la población en diálisis y las intervenciones para modificar el estilo de vida son las maniobras con mayor impacto en la morbimortalidad de los enfermos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000; 36(3):646-61.

  2. Giles TD, Berk BC, Black HR, Cohn JN, Kostis JB, Izzo JL Jr, et al. Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich). 2005;7(9):505-12.

  3. Czarkowski M, Staszkow M, Kostyra K, Shebani Z, Niemczyk S, Matuszkiewicz-et al. Determining the accuracy of blood pressure measurement by the Omrom HEM-907 before and after hemodialysis. Blood Press Monit. 2009;14(5):232-8.

  4. National Institute for Health and Care Excellence (NICE). Hypertension in Adults. NICE quality standard 28 [QS28]. Published date: March 2013. Last updated: September 2015. Disponible en https:// www.nice.org.uk/guidance/qs28

  5. Shafi T, Waheed S, Zager PG. Management of hypertension in In-Center Hemodialisis Patients - An opinion- Based Update. Semin Dial. 2014 March;27(2):146-53.

  6. Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol. 2007;2:1228-34.

  7. Agarwal R, Andersen MJ, Bishu K, Saha C. Home blood pressure monitoring improves the diagnosis of hypertension in hemodialysis patients. Kidney Int. 2006;69(5):900-6.

  8. Townsend RR, Sica DA. Beyond conventional considerations: newer devices used in blood pressure measurement and management. Adv Chronic Kidney Dis. 2011 Jan;18(1):48-54.

  9. Rubin MF, Rosas SE, Chirinos JA, Townsend RR. Surrogate markers of cardiovascular disease in CKD: what’s under the Hood? Am J Kidney Dis. 2011;57(3):488-97.

  10. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, et al. Chronic Renal Insufficiency Cohort (CRIC) Study: Baseline Characteristics and Associations with Kidney Function. Clin J Am Soc Nephrol. 2009;4(8):1302-11.

  11. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20):2043-50.

  12. Fraser SDS, Roderick PJ, Mcintyre NJ, Harris S, Mcintyre CW, Fluck RJ, et al. Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care. BMC Fam Pract. 2013;14:88.

  13. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Greenland S, Kopple JD. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension. 2005;45:811-7.

  14. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, et al. “U” curve association of blood pressure and mortality in hemodialysis patients. Kidney Int. 1998;54(2):561-6.

  15. Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund-Bodegård K, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370(9594):1219-29.

  16. Lui M, Takahashi H, Morita Y, Maruyama S, Mizuno M, Yuzawa Y, et al. Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients. Nephrol Dial Transplant. 2003;18(3):563-9.

  17. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Álvarez V, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Eng J Med. 2002;347:797-805.

  18. Syrseloudis D, Tsioufis C, Andrikou I, Mazaraki A, Thomopoulos C, Mihas C, et al. Association of nighttime hypertension with central arterial stiffness and urinary albumin excretion in dipper hypertensive subjects. Hypertens Res. 2011;34:120-5.

  19. Oliveras A, Armario P, Martell-Clarós N, Ruilope LM, de La Sierra A; Spanish Society of Hypertension- Resistant Hypertension Registry. Urinary albumin excretion is associated with nocturnal systolic blood pressure in resistant hypertensives. Hypertension. 2011;57;556-60.

  20. Agarwal R, Light RP. GFR, proteinuria and circadian blood pressure. Nephrol Dial Transplant. 2009;24:2400-6.

  21. Agarwal R, Andersen MJ. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006;69(7):1175-80.

  22. Agarwal R, Kariyanna SS, Light RP. Prognostic value of circadian blood pressure variation in chronic kidney disease. Am J Nephrol. 2009;30:547-53.

  23. Judd E, Calhoun DA. Management of hypertension in CKD: beyond the Guidelines. Adv Chronic Kidney Dis. 2015 March;22(2):116-22.

  24. Mehta R, Drawz PE. Is nocturnal blood pressure reduction the secret to reducing the rate of progression of hypertensive chronic kidney disease? Curr Hypertens Rep. 2011 Oct;135(5):378-85.

  25. James PA, Oparil S, Carter BL, Cushman WC, Dennison- Himmelfarb C, Handler J, et al. 2014 Evidence- Based Guideline for the management of high blood pressure in adults report from the panel members appointed to the Eight Joint National Committee (JNC- 8). JAMA. 2014;311(5):507-20.

  26. Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guideline for the evaluation and management of blood pressure in Chronic Kidney Disease. Kidney Int Suppl. 2012;2(5):337-414.

  27. Parati G, Stergiou G, O’Brien E, Asmar E, Beilin L, Bilo G, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359-66.

  28. Minutolo R, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi B, et al. Assessment of achieved clinical and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study. Am J Kidney Dis. 2014;64(5):744-52.

  29. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, et al. Trial Group. In-Center Hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363(24):2287-300.

  30. Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension. 2009;53(3):500-7.

  31. Campese VM TA. Hypertension in dialysis patients. Philadelphia: Lippincott Williams & Wilkins, 2004.

  32. Santos SF, Peixoto AJ. Hypertension in dialysis. Curr Opin Nephrol Hypertens. 2005;14:111-8.

  33. Shafi T, Sozio SM, Bandeen-Roche KJ, Ephraim PL, Luly JR, St Peter WL, et al. The DecIDE Network Patient Outcomes in ESRD Study. Predialysis systolic blood pressure variability and outcomes in incident hemodialysis patients. J Am Soc Nephrol. 2014; April 25(4):799-809.

  34. Inrig JK, Van Buren P, Kim C, Vongpatanasin W, Povsic TJ, Toto R. Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell disfunction. Clin J Am Soc Nephrol. 2012 Aug;7(8):1300-9.

  35. Nakao N, Yoshimura A, Morita H, Takada M, KayanoT, Ideura T. Combination treatment of angiotensin- II receptor blocker and angiotensin-convertingenzyme inhibidor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117-24.

  36. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al.; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-53.

  37. Parving HH, Persson F, Lewis JB, Lewins EJ, Hollenberg NK; AVOID study investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-46.

  38. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204-13.

  39. Fried LF, Duckworth W, Zhang JH, O’Connor T, Brophy M, Emanuele N; VA NEPHRON-D investigators. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHROND). Clin J Am Soc Nephrol. 2009;4(2):361-8.

  40. Viazzi F, Leoncini G, Pontremoli R. Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system. High Blood Press Cardiovasc Prev. 2013;20(4):273-82.

  41. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43(1):4-9.

  42. Agarwal R, Sinha AD. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens. 2012;6(5):299-308.

  43. Dussol B, Moussi-Frances J, Morange S, Somma- Delpero C, Mundler O, Berland Y. A pilot study comparing furosemide and hydrochlorothiazide in patients withhypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens (Greenwich). 2012;14(1):32-7.

  44. Verdalles U, de Vinuesa SG, Goicoechea M, Quiroga B, Reque J, Panizo N, et al. Utility or bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD). Nephrol Dial Transplant. 2012;27 (Suppl 4):iv31-5.

  45. McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW, et al. A randomized trial of dietary sodium intake restriction in CKD. J Am Soc Nephrol. 2013;24(12):2096-103.

  46. Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Jansen WM, Lambers Heerspink HJ, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ. 2011;343:d4366.

  47. Vogt L, Wanders F, Boomsma F, de Zeeuw D, Navis G. Effect of Dietary Sodium and Hydrochlorothiazide on the Anti-proteinuric Efficacy of Losartan. J Am Soc Nephrol. 2008;19(5):999-1007.

  48. 48.Strom BL, Yaktine AL, Oria M, Eds.; Committee on the Consequences of Sodium Reduction in Populations; Food and Nutrition Board; Board on Population Health and Public Health Practice; Institute of Medicine (US). Sodium Intake in Populations: Assessment of Evidence. Washington DC: The National Academies Press; 2013.

  49. Hermida RC, Ayala DE, Mojón A, Fernandez JR. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011;34(6):1270-6.

  50. Garimella PS, Uhlig K. Current issues in the management and monitoring of hypertension in chronic kidney disease. Curr Opin Nephrol Hypertens. 2013 November;22(6):599-606.

  51. MacLaughlin HL, Sarafidis PA, Greenwood SA, Campbell KL, Hall WL, Macdougall IC. Compliance with structures weight loss program is associated with reduce systolic blood pressure in obese patients with chronic kidney disease. Am J Hypertens. 2012;25(9):1024-9.

  52. Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-54.




2020     |     www.medigraphic.com